rs183192651
Positions:
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2
The NM_000719.7(CACNA1C):c.4317C>T(p.Asn1439Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000849 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000039 ( 0 hom. )
Consequence
CACNA1C
NM_000719.7 synonymous
NM_000719.7 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.99
Genes affected
CACNA1C (HGNC:1390): (calcium voltage-gated channel subunit alpha1 C) This gene encodes an alpha-1 subunit of a voltage-dependent calcium channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane segments and forms the pore through which ions pass into the cell. The calcium channel consists of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. There are multiple isoforms of each of these proteins, either encoded by different genes or the result of alternative splicing of transcripts. The protein encoded by this gene binds to and is inhibited by dihydropyridine. Alternative splicing results in many transcript variants encoding different proteins. Some of the predicted proteins may not produce functional ion channel subunits. [provided by RefSeq, Oct 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -19 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.44).
BP6
Variant 12-2664909-C-T is Benign according to our data. Variant chr12-2664909-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 379152.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=2.99 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.000525 (80/152360) while in subpopulation AFR AF= 0.00192 (80/41582). AF 95% confidence interval is 0.00158. There are 0 homozygotes in gnomad4. There are 42 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High AC in GnomAd4 at 80 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1C | NM_000719.7 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | ENST00000399655.6 | NP_000710.5 | |
CACNA1C | NM_001167623.2 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | ENST00000399603.6 | NP_001161095.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1C | ENST00000399603.6 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 5 | NM_001167623.2 | ENSP00000382512.1 | ||
CACNA1C | ENST00000399655.6 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | NM_000719.7 | ENSP00000382563.1 | ||
CACNA1C | ENST00000682544.1 | c.4551C>T | p.Asn1517Asn | synonymous_variant | 37/50 | ENSP00000507184.1 | ||||
CACNA1C | ENST00000406454.8 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/48 | 5 | ENSP00000385896.3 | |||
CACNA1C | ENST00000399634.6 | c.4284C>T | p.Asn1428Asn | synonymous_variant | 34/47 | 5 | ENSP00000382542.2 | |||
CACNA1C | ENST00000683824.1 | c.4482C>T | p.Asn1494Asn | synonymous_variant | 36/48 | ENSP00000507867.1 | ||||
CACNA1C | ENST00000347598.9 | c.4461C>T | p.Asn1487Asn | synonymous_variant | 37/49 | 1 | ENSP00000266376.6 | |||
CACNA1C | ENST00000344100.7 | c.4383C>T | p.Asn1461Asn | synonymous_variant | 35/47 | 1 | ENSP00000341092.3 | |||
CACNA1C | ENST00000327702.12 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/48 | 1 | ENSP00000329877.7 | |||
CACNA1C | ENST00000399617.6 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/48 | 5 | ENSP00000382526.1 | |||
CACNA1C | ENST00000682462.1 | c.4407C>T | p.Asn1469Asn | synonymous_variant | 35/47 | ENSP00000507105.1 | ||||
CACNA1C | ENST00000683781.1 | c.4407C>T | p.Asn1469Asn | synonymous_variant | 35/47 | ENSP00000507434.1 | ||||
CACNA1C | ENST00000683840.1 | c.4407C>T | p.Asn1469Asn | synonymous_variant | 35/47 | ENSP00000507612.1 | ||||
CACNA1C | ENST00000683956.1 | c.4407C>T | p.Asn1469Asn | synonymous_variant | 35/47 | ENSP00000506882.1 | ||||
CACNA1C | ENST00000399638.5 | c.4401C>T | p.Asn1467Asn | synonymous_variant | 36/48 | 1 | ENSP00000382547.1 | |||
CACNA1C | ENST00000335762.10 | c.4392C>T | p.Asn1464Asn | synonymous_variant | 36/48 | 5 | ENSP00000336982.5 | |||
CACNA1C | ENST00000399606.5 | c.4377C>T | p.Asn1459Asn | synonymous_variant | 36/48 | 1 | ENSP00000382515.1 | |||
CACNA1C | ENST00000399621.5 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382530.1 | |||
CACNA1C | ENST00000399637.5 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382546.1 | |||
CACNA1C | ENST00000402845.7 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000385724.3 | |||
CACNA1C | ENST00000399629.5 | c.4368C>T | p.Asn1456Asn | synonymous_variant | 35/47 | 1 | ENSP00000382537.1 | |||
CACNA1C | ENST00000682336.1 | c.4359C>T | p.Asn1453Asn | synonymous_variant | 35/47 | ENSP00000507898.1 | ||||
CACNA1C | ENST00000399591.5 | c.4284C>T | p.Asn1428Asn | synonymous_variant | 34/46 | 1 | ENSP00000382500.1 | |||
CACNA1C | ENST00000399595.5 | c.4284C>T | p.Asn1428Asn | synonymous_variant | 34/46 | 1 | ENSP00000382504.1 | |||
CACNA1C | ENST00000399649.5 | c.4278C>T | p.Asn1426Asn | synonymous_variant | 34/46 | 1 | ENSP00000382557.1 | |||
CACNA1C | ENST00000399597.5 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382506.1 | |||
CACNA1C | ENST00000399601.5 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382510.1 | |||
CACNA1C | ENST00000399641.6 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382549.1 | |||
CACNA1C | ENST00000399644.5 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | 1 | ENSP00000382552.1 | |||
CACNA1C | ENST00000682835.1 | c.4317C>T | p.Asn1439Asn | synonymous_variant | 35/47 | ENSP00000507282.1 | ||||
CACNA1C | ENST00000683482.1 | c.4308C>T | p.Asn1436Asn | synonymous_variant | 35/47 | ENSP00000507169.1 | ||||
CACNA1C | ENST00000682686.1 | c.4284C>T | p.Asn1428Asn | synonymous_variant | 34/46 | ENSP00000507309.1 |
Frequencies
GnomAD3 genomes AF: 0.000519 AC: 79AN: 152242Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
79
AN:
152242
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000112 AC: 28AN: 249452Hom.: 0 AF XY: 0.0000961 AC XY: 13AN XY: 135250
GnomAD3 exomes
AF:
AC:
28
AN:
249452
Hom.:
AF XY:
AC XY:
13
AN XY:
135250
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461562Hom.: 0 Cov.: 31 AF XY: 0.0000344 AC XY: 25AN XY: 727056
GnomAD4 exome
AF:
AC:
57
AN:
1461562
Hom.:
Cov.:
31
AF XY:
AC XY:
25
AN XY:
727056
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000525 AC: 80AN: 152360Hom.: 0 Cov.: 33 AF XY: 0.000564 AC XY: 42AN XY: 74512
GnomAD4 genome
AF:
AC:
80
AN:
152360
Hom.:
Cov.:
33
AF XY:
AC XY:
42
AN XY:
74512
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 18, 2017 | Variant summary: The CACNA1C c.4317C>T (p.Asn1439Asn) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 42/276920 control chromosomes, predominantly observed in the African subpopulation at a frequency of 0.001666 (40/24008). This frequency is about 167 times the estimated maximal expected allele frequency of a pathogenic CACNA1C variant (0.00001), suggesting this is likely a benign polymorphism found primarily in the populations of African origin. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign/likely benign. The variant of interest has not, to our knowledge, been reported in affected individuals via publications nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 10, 2015 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
CACNA1C-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 09, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 01, 2020 | - - |
Long QT syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 30, 2023 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 29, 2016 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at